Scholarlink

Background <p>Sentinel lymph node biopsy (SLNB) is performed to guide recommendations on adjuvant treatments for invasive breast cancer. However, studies have shown oncological safety without SLNB in low-risk patients. We aimed to determine the clinical benefits of delaying SLNB (d-SLNB), if upfront axillary staging was omitted in patients with low-risk invasive breast cancers.</p> Methods and materials <p>A retrospective hypothetical simulated analysis. Patients who had breast surgery and SLNB between 2019 and 2021 were included. Patients with low-risk invasive cancers were identified based on preoperative histopathology (≥ 65 years, Luminal A-like, T1, cN0, Grade 1–2). Outcome analyses were based on the Actual clinical management compared to two different hypothetical Scenarios: (A) upfront SLNB omission only, and (B) upfront SLNB omission with d-SLNB. Primary endpoints were proportion of patients suitable for SLNB omission, outcome of d-SLNB and changes in adjuvant treatments. Secondary endpoint was surgical costs.</p> Result <p>Of 712 patients, 205 (30%) had low-risk invasive cancers and eligible for SLNB omission. In Scenario A, 25 (12%) patients with SLN metastases would have understaged. If Scenario B was applied, the false negative rate of axillary staging would reduce from 25 (12%) to 12 (6%) patients, <i>p</i> &lt; 0.001. On average, adjuvant treatments were given to 73% (Actual clinical setting) vs. 27% (Scenario A) vs. 55% (Scenario B), <i>p</i> &lt; 0.001. Based on 100 patients, d-SLNB was associated with an incremental cost of 55,000 EUR per 100 patients.</p> Conclusion <p>Although upfront SLNB omission was associated with missed SLN metastases, majority of low-risk invasive cancers were SLN negative. Delayed-SLNB could provide additional useful information to guide adjuvant treatments.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

The outcome of selective delayed sentinel lymph node biopsy following upfront omission of axillary staging in low-risk invasive breast cancers: a retrospective hypothetical simulated analysis

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年8月12日

查看全文
  • Albin Bengtsson,
  • Karolina Larsson,
  • Kian Chin

摘要

Background

Sentinel lymph node biopsy (SLNB) is performed to guide recommendations on adjuvant treatments for invasive breast cancer. However, studies have shown oncological safety without SLNB in low-risk patients. We aimed to determine the clinical benefits of delaying SLNB (d-SLNB), if upfront axillary staging was omitted in patients with low-risk invasive breast cancers.

Methods and materials

A retrospective hypothetical simulated analysis. Patients who had breast surgery and SLNB between 2019 and 2021 were included. Patients with low-risk invasive cancers were identified based on preoperative histopathology (≥ 65 years, Luminal A-like, T1, cN0, Grade 1–2). Outcome analyses were based on the Actual clinical management compared to two different hypothetical Scenarios: (A) upfront SLNB omission only, and (B) upfront SLNB omission with d-SLNB. Primary endpoints were proportion of patients suitable for SLNB omission, outcome of d-SLNB and changes in adjuvant treatments. Secondary endpoint was surgical costs.

Result

Of 712 patients, 205 (30%) had low-risk invasive cancers and eligible for SLNB omission. In Scenario A, 25 (12%) patients with SLN metastases would have understaged. If Scenario B was applied, the false negative rate of axillary staging would reduce from 25 (12%) to 12 (6%) patients, p < 0.001. On average, adjuvant treatments were given to 73% (Actual clinical setting) vs. 27% (Scenario A) vs. 55% (Scenario B), p < 0.001. Based on 100 patients, d-SLNB was associated with an incremental cost of 55,000 EUR per 100 patients.

Conclusion

Although upfront SLNB omission was associated with missed SLN metastases, majority of low-risk invasive cancers were SLN negative. Delayed-SLNB could provide additional useful information to guide adjuvant treatments.